Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Medically reviewed by Katlein Franca, MD When psoriasis affects the scalp, it causes thick, silvery-white or gray scales that may be inflamed and itchy. You may also feel burning or other discomfort.

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

For example, involvement of a hand is about 1% BSA, psoriasis on both knees about 2%, and the chest about 5-6%, said Asempa. Involvement of problematic areas -- scalp, intertriginous sites ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater reduction in skin thickening compared to etanercept and apremilast in the in vivo model SFA-002 reduced key ...